ProQR Therapeutics (PRQR) Capital Expenditures (2013 - 2026)
ProQR Therapeutics (PRQR) posted Capital Expenditures of $192002.3 for Q1 2026, down 89.11% sequentially from $1.8 million in Q4 2025, and down 18.51% YoY from $235622.1 in Q1 2025.
ProQR Therapeutics (PRQR) Capital Expenditures (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported Capital Expenditures for 14 years, with the latest figure at $192002.3 in Q1 2026.
- Quarterly Capital Expenditures fell 18.51% year-over-year to $192002.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 39.59% YoY) and the FY2025 annual result came in at $1.2 million, down 21.64% from the prior year.
- Capital Expenditures fell to $192002.3 in Q1 2026 per PRQR's latest filing, from $1.8 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $2.9 million in Q4 2024 and troughed at -$795216.8 in Q1 2024.
- A 5-year average of $404588.1 and a median of $114327.9 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures surged 809.47% in 2022, then sank 444.76% in 2024.
- Over 5 years, Capital Expenditures stood at $1.5 million in 2022, then jumped by 57.93% to $2.3 million in 2023, then climbed by 25.45% to $2.9 million in 2024, then sank by 38.99% to $1.8 million in 2025, then slumped by 89.11% to $192002.3 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $192002.3, $1.8 million, and -$197570.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | 192,002.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 192,002.29 |
| Mar 31, 2026 | 192,002.29 |
| Dec 31, 2025 | 1.76 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Sep 30, 2025 | -197,570.31 |
| Sep 30, 2025 | -197,570.31 |
| Jun 30, 2025 | 114,327.93 |
| Jun 30, 2025 | 114,327.93 |
| Mar 31, 2025 | 235,622.11 |
| Mar 31, 2025 | 235,622.11 |
| Dec 31, 2024 | 2.89 Mn |
| Dec 31, 2024 | 2.89 Mn |
| Sep 30, 2024 | -314,090.78 |
| Sep 30, 2024 | -314,090.78 |
| Jun 30, 2024 | 287,528.98 |
| Jun 30, 2024 | 287,528.98 |
| Mar 31, 2024 | -795,216.81 |
| Mar 31, 2024 | -795,216.81 |
| Dec 31, 2023 | 2.30 Mn |
| Dec 31, 2023 | 2.30 Mn |